{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-22-000110","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2022-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.529969+00:00","generated_at":"2026-06-21T12:46:53.197570+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"LivaNova's RECOVER depression trial enrollment expanded to 425 unipolar patients after interim analysis","bullets":["Independent Statistical Analysis Committee advised continuing enrollment to 425 unipolar patients, up from 400.","Interim analyses occur every 25 patients; cessation of RCT enrollment when predictive probability threshold met.","Final analysis after 12-month follow-up of last RCT patient; data to support CMS reimbursement reconsideration for VNS Therapy.","Company disclosed the update via Form 8-K on November 28, 2022, regarding event on November 23, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-22-000110","json":"https://secwatch.observer/filing/0001639691-22-000110.json","markdown":"https://secwatch.observer/filing/0001639691-22-000110.md","text":"https://secwatch.observer/filing/0001639691-22-000110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969122000110/0001639691-22-000110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969122000110/livn-20221123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:46:53.197570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}